Reckitt Benckiser Group plc Faces Class Action Lawsuit Notice
Reckitt Benckiser Group plc Lawsuit Notification
The Gross Law Firm extends this notification to all shareholders of Reckitt Benckiser Group plc (RBGLY), informing them about a class action lawsuit currently in progress.
Class Period Details
Investors who acquired shares of RBGLY during the specified class period from January 13, 2021, to July 28, 2024, are encouraged to seek information regarding potential appointments as lead plaintiffs. Importantly, becoming a lead plaintiff is not a prerequisite for participating in any potential recovery.
Allegations Against Reckitt Benckiser
The allegations state that the company failed to disclose critical information during the class period, particularly concerning the risks associated with their cow's milk-based formula, Enfamil. It is claimed that preterm infants were at heightened risk for developing serious health conditions as a result of consuming this product. These oversights likely impacted Reckitt's sales and exposure to legal claims.
Important Deadlines
Shareholders should take note of the deadline for registering for this class action: August 4, 2025. Prompt registration is crucial to ensure your participation in the proceedings.
Next Steps for Interested Shareholders
Once you register, you will be added to a portfolio monitoring service that provides updates regarding the lawsuit. Having this information can help investors remain informed about the progress of their case. Remember, there are no costs or obligations involved in this participation.
Why Choose Gross Law Firm?
The Gross Law Firm takes pride in being a leading national law firm focused on class action cases. Their mission is to protect investor rights by addressing issues of deceit and misleading practices within companies. Their commitment is to hold corporations accountable for their statements and behaviors that may lead to stock price inflation through misleading claims.
Contact Information
If you have questions or wish to register, reach out to The Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of this lawsuit?
The lawsuit aims to address potential wrongdoings by Reckitt Benckiser Group plc related to misleading statements about their products, specifically Enfamil.
Who can join the class action?
Anyone who purchased shares of RBGLY during the class period from January 13, 2021, to July 28, 2024, is eligible to join.
What is the deadline for registering?
The deadline to register for the class action lawsuit is August 4, 2025.
Will it cost me to participate?
No, there are no costs or obligations to participate in this case.
How will I be updated about the case progress?
Once registered, you will be enrolled in a monitoring service that provides you with updates during the case lifecycle.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
